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Background Transcription of interleukin-6 (IL-
6) can be regulated by a promoter sequence 
located -5 Kb upstream of its transcription start 
site. 
Result Heterogeneous nuclear ribonucleoprotein 
A1 and A2/B1 (HNRNPA1 and HNRNPA2/B1) 
show interaction with the upstream promoter 
element and regulates IL-6 promoter activity.  
Conclusion HNRNPA1 is a novel 
transcriptional regulator of IL-6.  
Significance HNRNP proteins may play 
important roles during inflammation.  
 
Summary 
Interleukin-6 (IL-6) is an important pro-
inflammatory cytokine involved in many 
autoimmune and inflammatory diseases. We 
have shown previously that a region from -5307 
to -5202 bp upstream of the IL-6 transcriptional 
start site is responsible for basal IL-6 gene 
expression and that there were DNA binding 
proteins involved from EMSA and transient 
expression experiments. Here we have combined 
surface plasmon resonance technology with 
mass spectrometry analysis and identified 
nuclear proteins bound to this region. 
HNRNPA1 and HNRNPA2/B1 were found 
consistently. EMSA supershift and chromatin 
immunoprecipitation assays confirmed the 
involvement of HNRNPA1, but not 
HNRNPA2/B1. Knocking down HNRNPA1 
expression by siRNA resulted in reduced IL-6 
transcriptional activity as assessed from 
transfection experiments using reporter 
constructs, mRNA and protein measurements. 
Overexpression of HNRNPA1 cDNA increased 
IL-6 mRNA expression. This regulation was 
dependent on the presence of the sequence from 
-5307 to -5202 bp of the IL-6 gene. Thus, 
HNRNPA1 is a novel transcriptional regulator of 
IL-6 expression, acting via the 5’ flanking 
sequence of the gene. 
 
Introduction 
Interleukin-6 (IL-6) is a key cytokine in both 
innate and adaptive immune responses. 
Dysregulation of IL-6 signalling is implicated in 
many disease processes characterised by chronic 
inflammation and autoimmunity (1). It is a 
pleiotropic cytokine produced in numerous cell 
types, but the primary sources are cells of the 
myeloid lineage (such as monocytes, 
macrophages, B cells), epithelial, endothelial, 
and muscle cells. Its function includes promotion 
of inflammation by induction of chemokines and 
adhesion molecules, but it also produces the 
interleukin 1 receptor antagonist (IL-1ra) and 
inhibitor of metalloproteinases. It is in addition a 
growth factor for a diverse population of cells 
and tissues including B-cells, T cells, endothelial 
cells, cardiac and skeletal muscle cells. It is also 
referred to as a myokine in the literature on 
muscle function and exercise.  
IL-6 gene transcription can be induced by 
other pro-inflammatory cytokines such as IL-1 
and tumour necrosis factor alpha (TNFα) in 
addition to other stimuli such as bacterial 
lipopolysaccharide (LPS). Functional cis-
regulatory elements described to date are 
transcription factor binding sites for NFκB (2), 
IRF-1 (3), AP-1 (4), C/EBP (5) and SP1 (6). 
These cis-acting elements are all located within 
1.2 kb upstream of the transcription start site 
(TSS) of the IL-6 gene. A functional SNP at -
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174 bp upstream of the IL-6 TSS (rs1800795) is 
the most extensively studied SNP and showed 
association with diseases including systemic 
onset juvenile arthritis (sJIA) (7,8), Systemic 
Lupus Erythematosus (SLE) (9), and 
cardiovascular disease (10-14).  
Previously we have reported that IL-6 gene 
transcription could be regulated beyond the 1 kb 
5’ flanking region and identified cis-acting 
sequences as far as -5 kb upstream of the IL-6 
TSS to be important for basal IL-6 gene 
transcription (15). A specific region from -5307 
bp to -5152 bp was found to bind nuclear 
proteins and reporter assays in HeLa cells 
showed higher IL-6 basal transcription activity. 
In this report, we have applied surface plasmon 
resonance (SPR) technology and mass 
spectrometry analysis to identify the nuclear 
proteins that bind to this region. Further 
experiments confirmed the presence of 
HNRNPA1 which was found to have a cis-
regulatory role in IL-6 transcription in cultured 
cells.  
 
Experimental procedures 
Cell culture and nuclear extraction-HeLa cells 
were maintained in Dulbeco’s modified Eagle 
medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) in a humidified atmosphere 
of 5% CO2 at 37°C.  
Nuclear extracts were prepared from 
exponentially growing HeLa cells following the 
method described previously (15). The 
resuspension buffer contained 10 mM HEPES-
KOH pH 7.9, 420 mM NaCl, 0.2 mM EDTA, 
0.1 mM EGTA, 25% v/v glycerol, 1 mM DTT 
and protease and phosphatase inhibitors. Protein 
concentration was quantified using Bio-Rad 
Bradford protein assay.  
Surface Plasmon Resonance (SPR)-The SPR 
experiment was carried out using a BIAcore 
T100 with Sensor chip SA (Biacore). The DNA 
fragment containing sequence from -5307 to -
5152 bp upstream of IL-6 TSS (IL6-155) was 
amplified using a forward primer 5’-biotin-
TGGCTCAGACATAGACCACTG-3’ and a 
reverse primer 5’-
TATTGTTCCAAGGGGTGCTG-3’, and 
purified on Qiagen PCR columns. The SA chip 
surface was activated by injection of 1 M NaCl 
in 50 mM NaOH for 1 min three times. Biotin-
labelled PCR product at 2 ng/mL in 0.5 M NaCl 
was injected onto the chip surface at a flow rate 
of 5 µL/min for 30 min. Approximately 1,500 
RU (arbitrary resonance units) was achieved per 
flow cell. Empirically in the BIAcore technology, 
1 ng of a globular protein or 0.78 ng of a DNA 
molecule bound at the surface gives a response 
of 1000 RU (16). 
For protein-DNA interaction analyses, 20 to 
200 ng/µL nuclear proteins were first incubated 
with 10 ng/µL of poly [dI-dC], as a competitor 
for non-specific protein binding to the DNA chip, 
in binding buffer containing 20 mM HEPES pH 
7.6, 50 mM KCl, 5mM MgCl2, 1 mM EDTA, 40 
ng/µL BSA and 0.05% P20 surfactant and then 
applied to the DNA-immobilised chip at a rate of 
1 µL/min. The sensorgrams were recorded 
automatically and adjusted by subtracting the 
baseline response recorded immediately before 
the injection of each sample when only buffer 
plus BSA was applied. The usage of BSA was to 
block non-specific binding sites on the DNA 
surface. A flow cell without immobilised DNA 
served as a non-specific binding control. At the 
end of each cycle, bound proteins were eluted by 
two-pulse injections of 0.05% SDS to regenerate 
the chip. For protein recovery, all four flow cells 
on the chip were immobilised with IL6-155 
DNA and the bound proteins recovered to 
collection tubes by using the ‘Injection and 
Recovery’ function of the BIAcore T100. 
Multiple cycles and repeats were applied to 
obtain sufficient protein for mass spectrometry 
analysis. The recovered samples were 
concentrated using a vacuum dryer and then 
resolved on a 10% Bis-Tris NuPAGE gel 
(Invitrogen) followed by silver staining using 
SilverQuest Silver Staining Kit or colloidal 
Coomassie Blue (Invitrogen). 
Mass Spectrometry analysis-Gel bands (stained 
with colloidal Coomassie Blue) were excised 
and washed three times in 50% (v/v) acetonitrile, 
dried in a vacuum centrifuge, reduced in 10 mM 
DTT in 5 mM ammonium bicarbonate pH 8.0 
for 45 min at 50oC and alkylated with 50 mM 
iodoacetamide in ammonium bicarbonate for 1 
hr at room temperature in the dark. Gel pieces 
were washed twice in 50% acetonitrile, vacuum 
dried, and then 50 ng sequence grade modified 
trypsin (Promega, Southampton, UK) in 5 mM 
ammonium bicarbonate was added to each dried 
gel piece. After allowing gel pieces to re-swell 
for 5 min, 5 µL of 5 mM ammonium bicarbonate 
was added and gel pieces were incubated at 37oC 
for 16 hr. Tryptic peptides were extracted three 
times with 50% (v/v) acetonitrile containing 5% 
(v/v) trifluoroactetic acid. Extracts from each gel 
piece were pooled and vacuum centrifuged to 
dryness. Peptides were finally resuspended in 5 
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µL of 0.1% (v/v) formic acid and stored at -20oC 
prior to mass spectrometric analysis. 
Analysis of tryptic peptides from digested 
bands was performed by nanoflow reversed-
phase liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) on an LTQ Orbitrap 
XL mass spectrometer (Thermo Scientific). 
Sample (5 µL) was injected onto a 300 µm i.d. x 
5 mm C18 PepMap guard column (5 µm bead 
size, 100 Å pore size, LC Packings, Netherlands) 
and washed for 3 min with 95% solvent A (water 
+ 0.1% FA) at a flow rate of 25 mL/min using an 
Ultimate 3000 system (Dionex). Reversed-phase 
chromatographic separation was then carried out 
on a 75 mm i.d. x 250 mm C18 PepMap nano 
LC column (3 µm bead size, 100 Å pore size; 
LC Packings, Netherlands) with a linear gradient 
of 5-50% solvent B (water/ACN 20%:80% v/v + 
0.1% FA). The mass spectrometer was operated 
in the data-dependent mode to automatically 
switch between MS and MS/MS acquisition. 
Survey full scan MS spectra (m/z 400 to 2000) 
were acquired in the Orbitrap with a resolution 
of 60,000 at m/z 400. The top 6 most intense 
ions were selected for collision induced 
dissociation. Target ions that had been selected 
for MS/MS were dynamically excluded for 60 
sec. For accurate mass measurement, the lock 
mass option was enabled using the 
polydimethylcyclosiloxane ion (m/z 455.12003) 
as an internal calibrant. For peptide 
identification, raw data files produced in 
Xcalibur software (Thermo Scientific) were 
processed in Mascot Distiller (V2.2) and 
searched against the IPI human database 
(version 20100213; 87,130 sequences). For 
searching, the MS tolerance was set to ±10 ppm 
and the MS/MS tolerance to 0.8 Da. One missed 
cleavage was allowed and carbamidomethylation 
(C) was set as a fixed modification. Methionine 
oxidation, acetylation (protein N-terminal), Glu-
>pyro-Glu (N-term Q) and deamidation (NQ) 
were set as variable modifications. Only peptides 
with ion scores >30 were accepted using a 
significance threshold of 0.05 and protein 
identifications had to have at least 2 unique 
peptides matched per protein. 
Electrophoretic mobility shift assay (EMSA) and 
supershift-EMSA was performed using the non-
radioactive LightShift Chemiluminescent EMSA 
kit (Pierce, Thermo Scientific). The biotinylated 
IL6-155 probe was the same as that used for the 
SPR work. Short 39 bp probes, used previously 
(15), were made by annealing primer pairs and 
labelled at the 3’ end using terminal 
deoxynucleotidyl transferase and biotin-11-
dUTP (Fermentas, Thermo Scientific). EMSAs 
were performed using 10 nM biotinylated probes 
incubated with 2 µg of nuclear proteins in 1x 
binding buffer (8% Ficoll, 20 mM HEPES, 50 
mM KCl, 1mM EDTA, 0.5 mM DTT, 40 ng/µL 
of poly [dI-dC] and 40 ng/µL BSA) for 30 min 
at 25°C. In experiments where competitor 
unlabelled probes were added, reactions were 
pre-incubated with unlabelled probes in 100-fold 
molar excess of the labelled probe at 25°C for 15 
min prior to the addition of the labelled probe. 
For supershift, nuclear proteins were pre-
incubated with 2 µg of antibody for 30 min at 
25°C. The reaction mixture was loaded and run 
on a 5% native polyacrylamide gel. Gels were 
transferred to Hybond-N+ nylon membrane (GE 
Healthcare) and immediately UV cross-linked. 
Streptavidin-horseradish peroxidase conjugate 
and the LightShift chemiluminescent substrate 
were used to detect biotin-labelled DNA. The 
nylon membranes were then visualised by 
exposing to X-ray film. Antibodies to 
HNRNPA1 (4B10), HNRNPA2/B (DP3B3) and 
normal mouse IgG were purchased from Santa 
Cruz Biotechnology. Pure HNRNPA1 protein 
was obtained from Origene Technologies and 
200 ng used in EMSA reactions as a positive 
control.   
Chromatin Immunoprecipitation Assay (ChIP)-
The ChIP procedure was performed using 
MAGnify ChIP kit (Invitrogen) following the 
manufacturer's instructions. Briefly, HeLa cells 
grown to 90-100% confluence were cross-linked 
by treatment with 1% formaldehyde for 10 min 
at room temperature. Glycine was added to a 
final concentration of 125 mM for 5 min to 
quench the cross-linking reaction. Cells were 
rinsed 3 times with cold PBS, collected and 
resuspended in kit Lysis buffer supplemented 
with protease inhibitors. Chromatin was sheared 
by sonication using a Bioruptor sonicator 
(Wolflabs) and diluted in the kit Dilution buffer. 
Antibodies against HNRNPA1, HNRNPA2/B or 
normal mouse IgG (negative control) was 
coupled to protein A/G Dynabeads and then 
incubated with diluted chromatin. Chromatin 
from ~2x105 cells was used in each reaction. The 
beads were washed several times with kit IP 
buffers 1 and 2 and then protein-DNA crosslinks 
were reversed in the appropriate kit buffer at 
55ºC for 15 min, followed by 65ºC for 15 min. 
The DNA was purified using DNA Purification 
Magnetic Beads. One tenth of input chromatin 
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was also treated in the same way and purified. 
DNA aliquots were analysed by PCR with a 
primer pair, 5’-
TATGGCTTCCAGGGTGAGAG-3’ and 5’-
TATTGTTCCAAGGGGTGCTG-3’, 
encompassing -5368 to -5152 bp. The PCR 
conditions were as follows: 95°C for 5 min, 30 
cycles of 95°C 30 s, 57°C for 30 s, and 72°C for 
30 s, followed by 72°C for 7 min extension step. 
The amplified DNA was electrophoresed on a 2% 
agarose gel and visualised by staining with 
ethidium bromide. As a negative control, a 
separate region of the IL-6 gene located between 
+641 and +896 bp relative to TSS was amplified 
using the primers: 5’-
AATGGGTCTGAAATCCATGC-3’, and 5’-
GGTGGGCTCTGAGGTATGAA-3’. The level 
of enrichment of the target DNA sequence was 
determined relative to the input chromatin. 
Transfection and luciferase reporter assay-
HeLa cells were seeded into 24-well plates and 
were transiently transfected with 10 nM 
HNRNPA1 or HNRNPA2B1 siRNA duplex 
(Applied Biosystems Silenser® Select siRNA) 
complexed with Lipofectamine RNAiMAX 
(Invitrogen) in serum-free medium, according to 
the manufacturer’s instructions. For control 
siRNA, Silencer® Select Negative Control #2 
was used. The cells were collected at 48 h after 
transfection for RNA and protein analysis. The 
sense and antisense sequences of HNRNPA1 
siRNA were 5’-
GAAUGGUUAUAAAGUGAUtt-3’ and 5’-
AUCACUUUUAUAACCAUUCca-3’, and 
those of HNRNPA2B1  siRNA were 5’-
GCAACCUUCUAACUACGGUtt-3’ and 5’-
ACCGUAGUUAGAAGGUUGCtg-3’.  
For co-transfection experiments, 100 ng of 
IL-6 promoter-luciferase constructs, bearing IL-
6 promoter sequence up to -5307 bp or -5202 bp 
upstream of a luciferase gene in pGL3-basic 
vector (15), were transfected into HeLa cells in a 
96-well plate using Lipofectamine LTX 
(Invitrogen). Six hours later, the media was 
replaced and cells subjected to siRNA 
transfection as described above. After a further 
48 h, cell extracts were prepared and the 
luciferase activity was measured with the 
Luciferase Assay System (Promega) on a TR71 
Microplate Luminometer (Applied Biosystems). 
Total protein was measured with Bradford assay 
to correct for differences in cell number. The 
luciferase activity assays were measured in 
triplicate in each experiment and shown as fold-
change relative to pGL3-control vector. 
To overexpress the HNRNPA1 protein, HeLa 
cells were transfected with 100 ng or 200 ng of 
vector pCMV6-XL5 (OriGene) harbouring 
human HNRNPA1 cDNA or the empty vector 
using Lipofectamine LTX. Cells were harvested 
48 hrs post-transfection. 
RNA extraction and quantitative real-time PCR 
(qPCR)-Total RNA was extracted using Trizol 
reagent (Invitrogen) according to the 
manufacturer’s protocol. One microgram of total 
RNA was reverse transcribed to cDNA using 
Qantitect reverse transcription kit (Qiagen) and 
qPCR was performed using Taqman gene 
expression assay (Applied Biosystems) and 
Solaris qPCR Gene Expression Master Mix 
(Thermal Scientific). All qPCR reactions were 
performed on a Mastercycler ep realplex PCR 
system (Eppendorf) with cycling conditions as 
follows: 15 minutes of denaturation at 95°C and 
then 40 cycles of 95°C for 15s, 60°C for 1 
minute. Relative levels of mRNA expression 
were calculated according to the ΔΔCT method 
(17) and normalised by comparison to RPLP0 
mRNA expression. 
Statistical analysis-All experiments were 
repeated at least three times. Data are presented 
as the mean ± SD. The significance of 
differences between experimental groups was 
determined with a two-tailed unpaired Student’s 
t-test with p<0.05 considered as significant. 
 
Results 
Identification of proteins bound to the region -
5307 bp to -5152 bp of the 5’flanking region of 
IL-6-To identify proteins bound to the IL-6 5’-
flanking region at -5307 bp to -5152 bp (referred 
to as IL6-155 in the following text), we utilised 
SPR technology and mass spectrometry. The 
SPR approach consists of immobilising ligands 
to a surface and then observing changes in the 
refractive index at the surface in real-time as 
molecules bind, and has long been used to study 
protein-DNA interactions (18). Biotinylated 
probes of IL6-155 were immobilised onto a 
Streptavidin-coated sensorchip. Approximately 
1,500 RU was achieved per flow cell, equivalent 
to 1.14 ng or 11.4 fmol of DNA.  
Nuclear proteins extracted from HeLa cells 
were passed across this surface and protein-
DNA interaction was recorded in real time as a 
sensorgram shown in Figure 1A. On the DNA-
immobilised surface, RU increased with time 
during injection, while no change was observed 
on the DNA-free surface, indicating that there 
were proteins specifically binding to the DNA 
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sequence. Further, the nuclear proteins bound to 
the DNA surface in a concentration-dependent 
manner (Figure 1B). Since concentrations higher 
than 100 ng/µL did not lead to an appreciably 
higher signal, this concentration of nuclear 
extract was chosen for protein recovery 
experiments. Regeneration of the DNA surface 
enabled multiple capture/recovery cycles to 
increase the overall yield for mass spectrometric 
analysis.  
Analysis of eluted material by SDS-PAGE 
and silver staining showed several protein bands 
between 35 and 45 kDa that were not seen in 
BSA buffer alone (Figure 1C). Sufficient 
material was collected from repeat injections to 
reveal visible bands by colloidal Coomassie 
Blue staining. These were excised, the protein 
digested with trypsin and extracted peptides 
analysed by LC-MS/MS. The majority of 
identified proteins belonged to the family of 
heterogeneous nuclear ribonucleoproteins 
(HNRNPs) and included isoforms of HNRNPA0, 
A1, A/B, A2/B1, C1/C2 and D0. These could all 
be unambiguously identified by the presence of 
isoform-specific peptide sequences. The highest 
scoring proteins in the four most intense bands 
were isoform A1-B of HNRNPA1 and isoform 
B1 of HNRNPA2/B1. In a repeat experiment, 
both of these proteins were again identified. The 
presence of these bound proteins is notable in 
that they are generally considered as RNA 
binding proteins involved in pre-mRNA splicing. 
However, previous reports have hinted at their 
DNA binding capacity in promoter regions of 
the KRAS (v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog), APOE (apolipoprotein E) 
and IL-10 genes (19-21).   
HNRNPA1 binds to the IL6-155 region both in 
vitro and in vivo-To confirm the presence of the 
two HNRNP molecules in the complex with IL6-
155 in vitro, EMSA supershift assays were 
performed using specific antibodies to the two 
HNRNPs. The nuclear protein-DNA complex 
was further ‘shifted’ by the addition of antibody 
against HNRNPA1, but not by non-specific 
mouse IgG or antibody against HNRNPA2/B1 
(Figure 2A). These results confirmed the 
involvement of HNRNPA1 in complex with the 
IL6-155 sequence in vitro. The binding of 
HNRNPA2/B1 to the DNA sequence was not 
confirmed by this method. 
To test if HNRNPA1 interacts with this 
region in vivo, we performed chromatin 
immunoprecipitation (ChIP) assays on 
paraformaldehyde cross-linked HeLa cells. The 
result showed binding of HNRNPA1 to the 
region between -5368 and -5152 bp, which 
contains the IL6-155 sequence, but not to a 
downstream region between +691 and +896 bp 
(Figure 2B). On the other hand, when 
immunoprecipitated with anti-HNRNPA2/B1, a 
faint band was observed for the region -5368 to -
5152 but not for the downstream region, 
suggesting a weak interaction between 
HNRNPA2/B1and the IL6-155 region.  
Regulation of IL-6 gene expression by 
HNRNPA1-To investigate the influence of 
HNRNPA1 on IL-6 transcription, we measured 
luciferase activities of IL-6 promoter constructs 
in the presence of siRNA to HNRNPA1. 
Specific siRNAs (siHNRNPA1 or siHNRNPA2) 
or non-specific control siRNA (siNeg#2) were 
co-transfected into HeLa cells with IL-6 
promoter-luciferase constructs, containing 
promoter sequence up to -5202 or to -5307 
(namely pGL3-IL6-5202 or pGL3-IL6-5307). 
Both siRNAs showed high efficiency and 
specificity as analysed by qPCR (Figure 3A). 
Transfection of siHNRNPA1 significantly 
inhibited luciferase activity from pGL3-IL6-
5307, but had the opposite effect on pGL3-IL6-
5202 where the cis-acting sequence was absent 
(Figure 3B). However, the overall transcriptional 
activity of the pGL3-IL6-5202 construct is very 
much diminished without the 155 bp region, as 
previously published. The suppression of IL-6 
reporter activity by siHNRNPA1 suggests that 
HNRNPA1 positively regulates IL-6 
transcription and this function is dependent on 
the IL6-155 region. In contrast, knockdown of 
HNRNPA2/B1 by specific siRNA increased 
reporter activities. Knockdown of either protein 
had little effect on the activity of the pGL3-
control vector. 
The physiological function of HNRNPA1 and 
HNRNPA2/B1 on IL-6 gene expression was 
further examined by measuring IL-6 mRNA 
levels in HeLa cells transfected with the specific 
siRNAs. In comparison with siNeg#2-
transfected control cells, siHNRNPA1-
transfected cells had significantly lower IL-6 
mRNA expression, further supporting the 
positive regulation of basal IL-6 transcription by 
HNRNPA1 (Figure 3C). Knockdown of 
HNRNPA2/B1 had no effect on IL-6 mRNA 
expression. The positive regulation of IL-6 
expression by HNRNPA1 was also demonstrated 
in HeLa cells overexpressing HNRNPA1. Here 
expression of IL-6 mRNA was significantly 
increased in cells transfected with expression 
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vector pCMV6-HNRNPA1 compared with the 
control empty vector pCMV6 (Figure 3D).   
The 5’ end of the IL6-155 sequence is crucial for 
protein binding-In our previous publication, we 
designed five short DNA probes spanning the 
IL6-155 sequence in an attempt to identify 
sequences necessary for protein binding. Four 
out of five probes (except probe -5249 to -5210) 
showed protein binding with probe -5307 to -
5268 giving the strongest signal (15). Here we 
competed the protein binding of the IL6-155 
probe with a 100-fold molar excess of unlabelled 
short probes in EMSA assays. The results 
showed that only probe -5307 to -5268 
completely abolished protein binding to IL6-155, 
with two probes -5220 to -5181 and -5191 to -
5152 exhibiting partial competition (Figure 4A). 
This indicates that region -5307 to -5268 is 
essential for protein binding. In addition, the 
addition of HNRNPA1 antibody was able to 
partially retard the protein-DNA band of probe -
5307 to -5268 (Figure 4B). Interestingly, a motif 
5’-TACAGA-3’, located in the middle of the 
region, is similar to the sequence found to be 
responsible for HNRNPA1 binding to the IL10 
promoter (21) (5’-TACACA-3’; Figure 4C). To 
investigate whether this motif also contributes to 
HNRNPA1 binding to IL6-155, we mutated the 
predicted motif (mut1) or a sequence close by 
(mut2) and tested their ability to bind nuclear 
proteins using EMSA. Figure 4D shows that 
mut1 completely abolished protein-DNA 
binding, while mut2 could still form a protein-
DNA complex like the wild-type probe. 
Moreover, protein binding to the wild-type probe 
was competed by unlabelled mut2 and wild-type 
probe, but not by the mut1 probe containing. 
 
Discussion 
In this study, using a combination of SPR 
technology and mass spectrometry we have 
identified some of the nuclear proteins bound to 
a distal promoter sequence of the IL-6 gene that 
we had previously defined to be important for 
basal IL-6 transcription. SPR enables real-time 
monitoring interactions occurring on the sensor 
surface and provides a sensitive and specific 
approach to detect subtle differences in binding 
kinetics and binding affinity between target 
molecules and their ligands. Recovery of 
material from the surface and identification by 
mass spectrometry provides a powerful means to 
screen for unknown partners to a protein or 
DNA immobilised on the sensor surface. Its use 
has been well demonstrated (22-24). The 
limitation of the approach is that the amount of 
DNA that can be immobilised onto the surface is 
limited (normally fmol), and so this limits the 
amount of material recovered. Regeneration of 
the chip surface however, allows multiple runs 
to be performed and accumulation of sufficient 
material for MS analysis, as demonstrated here. 
Our results have established that HNRNPA1 
is at least one of the regulators of IL-6 
transcription by interacting with sequence 
between -5307 bp to -5152 bp of the IL-6 
promoter. The interaction was confirmed by 
EMSA supershift. Second, ChIP assays showed 
that HNRNPA1 interacted with the region of 
genomic DNA in cell culture. Third, reduction of 
HNRNPA1 protein levels in cells by siRNA 
inhibited IL-6 promoter activity and mRNA 
expression, while its overexpression increased 
IL-6 expression.  
The HNRNPs are among the most abundant 
proteins in the eukaryotic cell nucleus and are 
involved in many aspects of mRNA processing. 
HNRNPA1 is the most studied and has primary 
roles in packaging of pre-mRNA into HNRNP 
particles, nuclear export of mature mRNA and 
selection of splice sites (25-29). The observed 
regulation of IL-6 mRNA by HNRNPA1 may be 
due to its action on pre-mRNA. However, our 
DNA binding and reporter assay data would 
argue against this.  Moreover, HNRNPA1 was 
reported to bind single-stranded telomeric DNA 
through its RNA recognition motifs (RRMs) 
(30,31). The fact that only one of two RRMs is 
sufficient to bind telomeric DNA raises the 
potential for HNRNPA1 to interact with double-
stranded DNA (dsDNA).  
Transcriptional regulatory roles of HNRNPs 
(including HNRNPA1) via binding to dsDNA 
were reported more than a decade ago (32-34). 
HNRNPA1 has since been shown to interact 
with promoter regions of the thymidine kinase 
gene (34), APOE (20), KRAS (19) and IL-10 
(21). How HNRNPA1 binds to dsDNA to 
modulate gene expression is still unclear. The 
binding motifs identified from different 
promoters are not conserved. HNRNPA1 has 
been shown to bind an ‘ATTT’ sequence with 
high affinity in the thymidine kinase gene. An 
‘AGGGT’ sequence was found to be important 
for HNRNPA1 binding to the APOE promoter. 
A parallel G-quaduplex DNA structure, similar 
to telomeric repeats, was shown to be 
responsible for binding in the KRAS promoter. 
The study on the IL-10 promoter and our own 
study suggest that the sequence ‘TACACA’ is 
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critical for binding. Donev et al. showed  that 
HNRNPA1 bound to DNA within a 36 bp 
sequence and this sequence was found widely 
dispersed throughout the genome (35). These 
observations imply that HNRNPA1 may play a 
structural role and/or behave as a co-activator.  
HNRNPA2/B1 was also isolated as an IL6-
155 binding protein, but we were unable to 
confirm any functional role this may have in 
regulating IL6 transcription; the ChIP assay 
suggested a weak, but discernible interaction, 
knockdown of HNRNPA2/B1 led to increased 
reporter activity, whilst the EMSA was negative, 
and overexpression of HNRNPA2/B1 in HeLa 
cells had no effect on IL-6 mRNA expression. It 
is possible that the antibodies used were not 
appropriate or that there are cell specific effects. 
Despite this, recent work by Guha et al. has 
implied that HNRNPA2 is a common 
transcriptional co-activator, functioning in 
response to mitochondrial respiratory stress 
(36,37). 
The importance of HNRNPA1 in IL-6 
transcription may have clinical implications 
since autoantibodies to the HNRNP family have 
been detected in systemic rheumatic diseases, 
such as SLE (38,39), in which IL-6 levels are 
raised (40). Moreover, the mRNA expression of 
HNRNPA1, E1 and K were shown to be 
significantly increased in myocardial samples 
from patients with aortic stenosis or ischemic 
cardiomyopathy (41), which is also characterised 
by elevated IL-6 levels. Our data demonstrate 
that HNRNPA1 can regulate IL-6 expression 
through interacting with its DNA. We propose 
that HNRNPA1 acts as part of a complex that 
alters chromatin structure to enhance basal 
expression. To fully investigate this possibility, 
we will need to use preparative methods to 
isolate the co-factors and then rebuild the 
transcriptional apparatus, and this is currently 
beyond the scope of this report.   
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Footnotes 
This research was supported by Arthritis Research UK (no. 17287). The work was undertaken at 
UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR 
Biomedical Research Centres funding scheme. The abbreviations used are: IL, interleukin; TNF, 
tumour necrosis factor; LPS, lipopolysaccharide; TSS, transcription start site;  IL6-155, -5307 bp to -
5152 bp upstream of IL-6 TSS; SPR, Surface Plasmon Resonance; EMSA, Electrophoretic mobility 
shift assay; ChIP, Chromatin Immunoprecipitation; LC-MS/MS, liquid chromatography tandem mass 
spectrometry; siRNA, small interference RNA; qPCR, quantitative real-time polymerase chain 
reaction; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; APOE, apolipoprotein E  
Figure Legends 
Figure 1 Isolation of nuclear proteins binding to IL-6-155. A) Sensorgrams of SPR depicting binding 
of nuclear proteins to the immobilised IL6-155 DNA fragment. Nuclear proteins were injected at 20 
ng/µL in binding buffer onto the chip surface with no DNA or with immobilised DNA at a rate of 1 
µL/min for 10 min. B) Sensorgrams of SPR depicting binding of nuclear proteins to the DNA surface 
at various concentrations. To regenerate the chip between each injection, 0.05% SDS was injected at a 
rate of 5 µL/min for 30 sec. Sensorgrams were adjusted to zero baseline level before injections. 
Nuclear proteins were injected at 20, 50, 100 and 200 ng/µL in binding buffer and sensorgrams were 
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adjusted by subtracting the response recorded on the surface without DNA. C) Separation of 
recovered samples by SDS-PAGE. Recovered protein from multiple SPR injections was loaded onto a 
10% NuPAGE Bis-Tris gel along with protein molecular weight marker and buffer control and the gel 
was silver-stained. Lanes: MW, molecular weight markers; Eluate, sample recovered from BIAcore 
(contains BSA from binding/elution buffer); BSA, running buffer with BSA; NE: nuclear extract (NE) 
in binding buffer with BSA. The bands marked by black arrows were clearly not present in the lane 
containing BSA alone,  and were therefore excised for LC-MS/MS analysis. 
Figure 2 EMSA supershift assay and chromatin immunoprecipitation. A) EMSA supershift with 
antibodies against HNRNPA1 and HNRNPA2/B. Nuclear extracts were pre-incubated with 2 µg of 
antibody for 30 min at 25°C before adding to biotin-labelled IL6-155 probe. The position of the 
supershifted band is indicated by a black arrow. A1 = anti-HNRNPA1; A2 = anti-HNRNPA2/B1; IgG 
= mouse IgG. B) ChIP of HeLa cells with anti-HNRNPA1, anti-HNRNPA2B1 or control mouse IgG, 
followed by PCR amplification of IL-6 promoter regions between positions -5368 and -5152 bp or 
positions +691 and +896 bp (negative control region), in input DNA or immunoprecipitated DNA 
samples. The amplification from input DNA reflects the amount of starting DNA and was used to 
determine the level of enrichment of the target DNA sequence. The gel image is representative of 
three separate experiments.  
Figure 3 Effect of HNRNPA1 siRNA knockdown and overexpression on IL-6 promoter reporter 
activity and mRNA expression. A) The effect of specific siRNA on mRNA expression of HNRNPA1 
and HNRNPA2/B1. The specific or negative control siRNAs (10 nM) were transfected into HeLa 
cells using Lipofectamine RNAiMAX for 48 hrs before cells were collected for RNA purification 
followed by qPCR analysis. B) Effect of siRNAs for HNRNPA1 or HNRNPA2/B1 on luciferase 
activities of IL-6 promoter reporter constructs.  100 ng of IL-6 promoter luciferase constructs, bearing 
IL-6 5’flanking sequence up to -5307 bp or -5202 bp (pGL3-IL6-5307 or pGL3-IL6-5202), were 
transfected into HeLa cells using Lipofectamine LTX. Six hrs later, cells were subject to siRNA 
transfection as described. Cell extracts were prepared 48 hrs later and the luciferase activities were 
measured and shown as fold-change relative to pGL3-control vector. C) IL-6 mRNA expression in 
HeLa cells transfected with siRNAs. The data shown are relative to cells transfected with siNeg#2 
control. D) IL-6 mRNA expression in HeLa cells transfected with vector encoding HNRNPA1 
(pCMV6-HNRNPA1) or empty vector (pCMV6). The data shown are relative to cells transfected with 
empty vector. All experiments were performed three times. The error bars represent the standard 
deviation (SD) of the three replicate experiments and p<0.05 was regarded as significant.  
Figure 4 Identification of HNRNPA1 binding sites in the IL-6 promoter. A) Nuclear proteins binding 
to biotin-labelled IL6-155 probe in EMSA. Competitive EMSA was performed using 100-fold molar 
excess of unlabelled short probes spanning the region. Unlabelled probes were: -5307 to -5268; -5278 
to -5239; -5249 to -5210; -5220 to -5181 and -5191 to -5152. B) EMSA supershift assays of biotin-
labelled probe -5307 to -5268. The super-shifted band due to anti-HNRNPA1 is indicated by a black 
arrow. Ab, antibody; A1, anti-HNRNPA1; A2, anti-HNRNPA2/B1; IgG, mouse IgG. C) DNA 
sequence of probe -5307 to -5268 and its derivatives, mut1 and mut2. D) Nuclear proteins binding to 
labelled probe -5307 to -5268 and mutants. Competitive EMSAs were performed using 100-fold 
molar excess of unlabeled probes: wt= wild-type probe; m1= mut1 probe; m2= mut2 probe.  
  
11 
 
Figure 1 
A. 
 
B. 
 
C. 
 
  
IL6-155
No DNA
Injection of NEBuffer Buffer Regeneration
-2000
-1500
-1000
-500
0
500
1000
1500
2000
2500
3000
0 100 200 300 400 500 600 700 800 900R
e
sp
o
n
se
 (R
U
)
Time (sec)
0
500
1000
1500
2000
2500
3000
3500
4000
0 200 400 600 800 1000 1200
R
e
sp
o
n
se
 (R
U
)
Time (sec)
20 ng/µl
50 ng/µl
200 ng/µl
100 ng/µl
66
kDa
45
30
21
97
Eluate BSA NEMW
12 
 
Figure 2 
A. 
 
B. 
    
 
  
Lane     1          2          3         4       5
Antibody     - - A1     A2      IgG
NE     - +          +          +       +
-5368 to -5152
+691 to +896
13 
 
Figure 3 
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Figure 4 
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